JinYao Pharmaceutical hits four consecutive limit-ups; company warns of risks

Tianjin Pharmaceutical (600488) hit the daily limit again on the 1st, securing a fourth consecutive limit-up. As of the time of writing, the stock was trading at 5.76 yuan per share, with a buy-limit order of up to 220,000 lots on the limit-up board.

In a notice released on the evening of March 31, the company said that, given that the company’s shares have hit the daily limit multiple times in the short term, but there has been no major change in the company’s fundamentals, the company’s share price may be subject to market sentiment overheating and irrational speculation. The company solemnly reminds all investors that after the stock price has experienced a large increase in the short term, there may be a risk of a sharp decline. Investors are urged to fully understand the risks of trading in the secondary market, enhance their risk awareness in a practical manner, make rational decisions, and invest prudently.

After self-examination, the company said its production and operating activities are currently normal, and there has been no major change in its day-to-day operating conditions. The market environment or industry policies have not undergone major adjustments; production costs and sales have not shown significant fluctuations; and internal production and operating order remains normal. The company has not found any media reports or market rumors that could potentially, or already, affect the trading price of the company’s shares, nor any hot-spot concept-related matters, etc.

For the first three quarters of 2025, the company achieved operating revenue of 2.232 billion yuan, down 13.24% year over year. Net profit attributable to shareholders of listed companies was 69.5399 million yuan, down 62.75% year over year. Net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 136 million yuan, down 26.06% year over year.